Umamaheswari Ramachandran

Array ( [id] => 16328405 [patent_doc_number] => 20200299371 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING PEGYLATED FAB' FRAGMENT OF ANTI-HUMAN NGF ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/087908 [patent_app_country] => US [patent_app_date] => 2017-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13600 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16087908 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16769793 [patent_doc_number] => 10980876 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Conjugate vaccine targeting a disease-causing biological protein [patent_app_type] => utility [patent_app_number] => 16/087799 [patent_app_country] => US [patent_app_date] => 2017-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 23 [patent_no_of_words] => 10997 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16087799 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17539916 [patent_doc_number] => 11305020 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-19 [patent_title] => Methods for reducing toxicity of a chemotherapeutic drug [patent_app_type] => utility [patent_app_number] => 16/086978 [patent_app_country] => US [patent_app_date] => 2017-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 11528 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16086978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18915795 [patent_doc_number] => 11878061 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-23 [patent_title] => Methods for improving the therapeutic index for a chemotherapeutic drug [patent_app_type] => utility [patent_app_number] => 16/086977 [patent_app_country] => US [patent_app_date] => 2017-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 13580 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16086977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17073789 [patent_doc_number] => 11110168 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-07 [patent_title] => Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent [patent_app_type] => utility [patent_app_number] => 16/085015 [patent_app_country] => US [patent_app_date] => 2017-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 93 [patent_no_of_words] => 18208 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16085015 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14069459 [patent_doc_number] => 20190083617 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => PHARMACEUTICAL FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/083321 [patent_app_country] => US [patent_app_date] => 2017-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12532 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16083321 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16222740 [patent_doc_number] => 20200247856 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => RECOMBINANT FOLLISTATIN-FC FUSION PROTEINS AND USE IN TREATING DUCHENNE MUSCULAR DYSTROPHY [patent_app_type] => utility [patent_app_number] => 16/082070 [patent_app_country] => US [patent_app_date] => 2017-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21906 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16082070 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17162973 [patent_doc_number] => 11149060 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-19 [patent_title] => Functionalized nanoparticles for enhanced affinity precipitation of proteins [patent_app_type] => utility [patent_app_number] => 16/076418 [patent_app_country] => US [patent_app_date] => 2017-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 15 [patent_no_of_words] => 17141 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 265 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16076418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12111903 [patent_doc_number] => 09867881 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-16 [patent_title] => 'Viscosity-reducing excipient compounds for protein formulations' [patent_app_type] => utility [patent_app_number] => 15/434379 [patent_app_country] => US [patent_app_date] => 2017-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16528 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15434379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11649147 [patent_doc_number] => 20170145049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'REFOLDING PROTEINS USING A CHEMICALLY CONTROLLED REDOX STATE' [patent_app_type] => utility [patent_app_number] => 15/422327 [patent_app_country] => US [patent_app_date] => 2017-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 10018 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15422327 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11820654 [patent_doc_number] => 20170209592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-27 [patent_title] => 'Delivery Agents Targeted to Degraded Elastic Fibers' [patent_app_type] => utility [patent_app_number] => 15/421604 [patent_app_country] => US [patent_app_date] => 2017-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 12407 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15421604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11864824 [patent_doc_number] => 20170232104 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'STABLE IGG4 BASED BINDING AGENT FORMULATIONS' [patent_app_type] => utility [patent_app_number] => 15/416289 [patent_app_country] => US [patent_app_date] => 2017-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 62452 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15416289 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19503829 [patent_doc_number] => 12115227 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-15 [patent_title] => Formulation for antibody and drug conjugate thereof [patent_app_type] => utility [patent_app_number] => 16/069391 [patent_app_country] => US [patent_app_date] => 2017-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 21 [patent_no_of_words] => 32892 [patent_no_of_claims] => 91 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 899 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16069391 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14868081 [patent_doc_number] => 20190284282 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => STABLE PHARMACEUTICAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 16/068294 [patent_app_country] => US [patent_app_date] => 2017-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6265 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16068294 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11588518 [patent_doc_number] => 20170112930 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-27 [patent_title] => 'Stable Protein-Containing Preparation Containing Argininamide or Analogous Compound Thereof' [patent_app_type] => utility [patent_app_number] => 15/400355 [patent_app_country] => US [patent_app_date] => 2017-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 10334 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15400355 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14018967 [patent_doc_number] => 20190071477 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-07 [patent_title] => Recombinant complement Factor H-immunoglobulin fusion protein with complement regulatory activity, and preparation method therefor and use thereof [patent_app_type] => utility [patent_app_number] => 16/021034 [patent_app_country] => US [patent_app_date] => 2016-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10273 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16021034 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13826665 [patent_doc_number] => 20190016817 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => BUFFERED FORMULATIONS OF BEVACIZUMAB [patent_app_type] => utility [patent_app_number] => 16/066464 [patent_app_country] => US [patent_app_date] => 2016-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15898 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16066464 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13729819 [patent_doc_number] => 20180369377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING ANTI-PD-L1 ANTIBODY AVELUMAB [patent_app_type] => utility [patent_app_number] => 16/060319 [patent_app_country] => US [patent_app_date] => 2016-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14764 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16060319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11497873 [patent_doc_number] => 20170072054 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-16 [patent_title] => 'Stable Aqueous Formulations of Adalimumab' [patent_app_type] => utility [patent_app_number] => 15/360678 [patent_app_country] => US [patent_app_date] => 2016-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 39941 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15360678 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11497713 [patent_doc_number] => 20170071897 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-16 [patent_title] => 'CARRIER-ANTIBODY COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME' [patent_app_type] => utility [patent_app_number] => 15/359569 [patent_app_country] => US [patent_app_date] => 2016-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 23329 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15359569 [rel_patent_id] =>[rel_patent_doc_number] =>)